XENON PHARMACEUTICALS INC (XENE) Stock Analyst Ratings
USA - NASDAQ:XENE - CA98420N1050 - Common Stock
42.67 USD
+0.37 (+0.87%)
44 USD
+1.33 (+3.12%)
ChartMill assigns a Buy % Consensus number of 87% to XENE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 55.42. This target is 29.88% above the current price.
XENE was analyzed by 25 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about XENE.
In the previous month the buy percentage consensus was at a similar level.
XENE was analyzed by 25 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-02 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-08-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-12 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-12 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-05-14 | Evercore ISI Group | Initiate | Outperform |
| 2025-05-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-13 | Needham | Maintains | Buy -> Buy |
| 2025-05-13 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-05-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-07 | Chardan Capital | Initiate | Buy |
| 2025-04-17 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-02-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-11 | Deutsche Bank | Initiate | Buy |
| 2024-12-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-13 | Needham | Reiterate | Buy -> Buy |
| 2024-11-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-10 | Raymond James | Reiterate | Outperform |
| 2024-10-01 | HC Wainwright & Co. | Initiate | Buy |
| 2024-09-03 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-12 | Needham | Maintains | Buy -> Buy |
| 2024-08-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-09 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-06-18 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-05-10 | Needham | Maintains | Buy -> Buy |
| 2024-05-10 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-05-10 | Citigroup | Maintains | Buy -> Buy |
| 2024-04-12 | Needham | Reiterate | Buy -> Buy |
| 2024-04-10 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
XENON PHARMACEUTICALS INC / XENE FAQ
What is the average price target for XENON PHARMACEUTICALS INC (XENE) stock?
25 analysts have analysed XENE and the average price target is 55.42 USD. This implies a price increase of 29.88% is expected in the next year compared to the current price of 42.67.
Can you provide the consensus rating for XENON PHARMACEUTICALS INC stock?
The consensus rating for XENON PHARMACEUTICALS INC (XENE) is 87.2 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover XENON PHARMACEUTICALS INC (XENE) stock?
The number of analysts covering XENON PHARMACEUTICALS INC (XENE) is 25.